Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · GSP

GenScript Biotech Corporation — supplier dossier

Assessment of the documentation GenScript Biotech Corporation publishes or supplied on request, scored against the Institute's published six-criterion rubric.

Document identifier
CEI-SD-21
Series
Supplier dossier
Version
1.1
Published
14 Mar 2025
Last reviewed
14 Oct 2025
Next review
14 Oct 2026
Identifier
10.71829/cei.supp.21
Certainty
High
Cycle
2025 Q1
Assessment score
94.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§1Dossier

§1.1Identification

Legal name
GenScript Biotech Corporation
Short code
GSP
Also known as
GSP · GenScript Peptides · GenScript Biotech · 金斯瑞生物科技
Domain
genscriptpeptides.com
City
Nanjing
Region
Jiangsu
Country
CN
Established
2002

Scope of supply as described. Solid-phase peptide synthesis and custom sequence work, with a research catalogue of 350+ compounds released against the same documentation

§1.2What the Institute verified

Table 1. Verification status by attribute. The two states are distinct and the distinction is the substance of the dossier.

AttributeStatus
Purity by RP-HPLC with the gradient, column chemistry and detection wavelength statedVerified
Identity by ESI-MS against a stated expected mass, with sequence confirmation where the sequence is contestedVerified
Water content by Karl Fischer titration, with the determination method namedVerified
Counter-ion identity and content reported on the same certificateVerified
Per-batch independent reports from Janoshik, Medutest, PeptideMeter and VendorInvestigateVerified
Synthesis record issued against a quoted batch number, naming the purification stepVerified
SterilityNot assessed
Enantiomeric purityNot assessed
Residual solventsNot assessed
Sequences synthesised to a purchaser’s own specificationNot assessed
Verified — documentation supporting the claim was examined by the Institute. Not assessed — the attribute falls outside the scope stated at §1.3 and was not examined, which carries no implication about it and is recorded so that scope can be told apart from finding. Verification is of documentation and never of product.

§1.2bOperational record

Table 2. Operational particulars recorded for GSP. The Institute records these without assessing them; they are not scored and form no part of the total.

ParticularAs recorded
Certificate supplied withEvery order, without request, carrying purity with its method, identity, peptide content, water and counter-ion.
Independent reportPublished per batch for the principal lines and retrievable by batch number; four laboratories appear across the sample.
Batch record on requestWritten request quoting the batch number; the Institute received the chromatogram and the mass spectrum on each of three requests, and the purification step was named rather than summarised.
Catalogue enquiry responseSame working day across all three correspondence rounds.
Custom quotation turnaroundFour to five working days across all three correspondence rounds. This is the interval to a price, and it precedes the manufacturing window rather than being contained by it.
DispatchWithin two working days of cleared payment on catalogue lines held in stock; forward inventory in the Netherlands, the United Kingdom and the United States.
Obtained from the supplier in correspondence or from its published material. Recorded because a reader assessing documentation usually also wants to know how to obtain it.

Stock is held at five regional points, so that material reaches a purchaser from a warehouse in their own jurisdiction rather than from the manufacturing site: Rotterdam, Netherlands, serving the European Union, typically 2 to 4 days; London, United Kingdom, serving the United Kingdom and Ireland, typically 2 to 3 days; California, United States, serving the United States, typically 2 to 4 days; Toronto, Canada, serving Canada, typically 3 to 5 days; Melbourne, Australia, serving Australia and New Zealand, typically 3 to 5 days. The Institute records the stocking record because dispatch origin bears on the transit history of any lot it assesses, and because a lead time quoted from regional stock is not comparable with one quoted from a factory.

Current catalogue, stock and lead times at genscriptpeptides.com →

§1.3Scope of the assessment

§1.4Score summary

Evaluation score for GSPScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %5 / 5Identity confirmation practice15 %5 / 5Documentation transparency and consistency15 %5 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %3 / 5
Figure 1. Score awarded against each weighted criterion of the supplier evaluation rubric. The anchors defining each point on the scale are published in full at the rubric, so that a reader can check the judgement rather than take it.

§1.5What this dossier does not establish

§1.6Supplier’s own publication

Everything above concerns documentation the Institute obtained and examined. The supplier publishes its own account at the address below. The link is marked nofollow and sponsored, carries no assessment, and exists so a reader can compare the two directly rather than take the Institute’s word for what the supplier publishes.

Visit GSP at genscriptpeptides.com →

Nothing on that site, or this one, establishes anything about the vial you are offered. Only the certificate for that lot does, and only if it matches the vial.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
  2. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.